Aktieanalys

Faron Pharmaceuticals: Interim Update from BEXMAB Study - Redeye

{newsItem.title}

Redeye Publicerad: 31 Oct 2022 15:03

Faron Pharmaceuticals

Faron has announced an interim trial update from the phase I/II BEXMAB study with lead candidate Bexmarilimab. Redeye is encouraged by the news and looks forward to further development updates of the study.

Länk till analysen i sin helhet: https://www.redeye.se/research/860757/faron-pharmaceuticals-interim-update-from-bexmab-study?utm_source=finwire&utm_medium=RSS

Nyheter om Faron Pharmaceuticals

Läses av andra just nu

Om aktien Faron Pharmaceuticals

Senaste nytt